Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 101

1.

Azvudine, a novel nucleoside reverse transcriptase inhibitor showed good drug combination features and better inhibition on drug-resistant strains than lamivudine in vitro.

Wang RR, Yang QH, Luo RH, Peng YM, Dai SX, Zhang XJ, Chen H, Cui XQ, Liu YJ, Huang JF, Chang JB, Zheng YT.

PLoS One. 2014 Aug 21;9(8):e105617. doi: 10.1371/journal.pone.0105617. eCollection 2014.

PMID:
25144636
[PubMed - in process]
Free PMC Article
2.

The role of steric hindrance in 3TC resistance of human immunodeficiency virus type-1 reverse transcriptase.

Gao HQ, Boyer PL, Sarafianos SG, Arnold E, Hughes SH.

J Mol Biol. 2000 Jul 7;300(2):403-18.

PMID:
10873473
[PubMed - indexed for MEDLINE]
3.

Interaction of reverse transcriptase (RT) mutations conferring resistance to lamivudine and etravirine: effects on fitness and RT activity of human immunodeficiency virus type 1.

Hu Z, Kuritzkes DR.

J Virol. 2011 Nov;85(21):11309-14. doi: 10.1128/JVI.05578-11. Epub 2011 Aug 17.

PMID:
21849432
[PubMed - indexed for MEDLINE]
Free PMC Article
4.

Phenotypic impact of HIV reverse transcriptase M184I/V mutations in combination with single thymidine analog mutations on nucleoside reverse transcriptase inhibitor resistance.

Ross L, Parkin N, Chappey C, Fisher R, Clair MS, Bates M, Tisdale M, Lanier ER.

AIDS. 2004 Aug 20;18(12):1691-6.

PMID:
15280780
[PubMed - indexed for MEDLINE]
5.

In vitro human immunodeficiency virus type 1 resistance selections with combinations of tenofovir and emtricitabine or abacavir and lamivudine.

Margot NA, Waters JM, Miller MD.

Antimicrob Agents Chemother. 2006 Dec;50(12):4087-95. Epub 2006 Sep 18.

PMID:
16982781
[PubMed - indexed for MEDLINE]
Free PMC Article
6.

Frequency of mutations conferring resistance to nucleoside reverse transcriptase inhibitors in human immunodeficiency virus type 1-infected patients in Korea.

Cho YK, Sung H, Ahn SH, Bae IG, Woo JH, Won YH, Kim DG, Kang MW.

J Clin Microbiol. 2002 Apr;40(4):1319-25.

PMID:
11923351
[PubMed - indexed for MEDLINE]
Free PMC Article
7.

2'-deoxy-4'-C-ethynyl-2-halo-adenosines active against drug-resistant human immunodeficiency virus type 1 variants.

Kawamoto A, Kodama E, Sarafianos SG, Sakagami Y, Kohgo S, Kitano K, Ashida N, Iwai Y, Hayakawa H, Nakata H, Mitsuya H, Arnold E, Matsuoka M.

Int J Biochem Cell Biol. 2008;40(11):2410-20. doi: 10.1016/j.biocel.2008.04.007. Epub 2008 Apr 11.

PMID:
18487070
[PubMed - indexed for MEDLINE]
8.

The HIV-1 reverse transcriptase M184I mutation enhances the E138K-associated resistance to rilpivirine and decreases viral fitness.

Kulkarni R, Babaoglu K, Lansdon EB, Rimsky L, Van Eygen V, Picchio G, Svarovskaia E, Miller MD, White KL.

J Acquir Immune Defic Syndr. 2012 Jan 1;59(1):47-54. doi: 10.1097/QAI.0b013e31823aca74.

PMID:
21997204
[PubMed - indexed for MEDLINE]
9.

Drug resistance and drug combination features of the human immunodeficiency virus inhibitor, BCH-10652 [(+/-)-2'-deoxy-3'-oxa-4'-thiocytidine, dOTC].

Taylor DL, Ahmed PS, Tyms AS, Wood LJ, Kelly LA, Chambers P, Clarke J, Bedard J, Bowlin TL, Rando RF.

Antivir Chem Chemother. 2000 Jul;11(4):291-301.

PMID:
10950391
[PubMed - indexed for MEDLINE]
10.

In vitro antiretroviral activity and in vitro toxicity profile of SPD754, a new deoxycytidine nucleoside reverse transcriptase inhibitor for treatment of human immunodeficiency virus infection.

Gu Z, Allard B, de Muys JM, Lippens J, Rando RF, Nguyen-Ba N, Ren C, McKenna P, Taylor DL, Bethell RC.

Antimicrob Agents Chemother. 2006 Feb;50(2):625-31.

PMID:
16436719
[PubMed - indexed for MEDLINE]
Free PMC Article
11.

Mutations in the non-nucleoside binding-pocket interfere with the multi-nucleoside resistance phenotype.

Van Laethem K, Witvrouw M, Pannecouque C, Van Remoortel B, Schmit JC, Esnouf R, Kleim JP, Balzarini J, Desmyter J, De Clercq E, Vandamme AM.

AIDS. 2001 Mar 30;15(5):553-61.

PMID:
11316991
[PubMed - indexed for MEDLINE]
12.

Broad nucleoside reverse-transcriptase inhibitor cross-resistance in human immunodeficiency virus type 1 clinical isolates.

Whitcomb JM, Parkin NT, Chappey C, Hellmann NS, Petropoulos CJ.

J Infect Dis. 2003 Oct 1;188(7):992-1000. Epub 2003 Sep 16.

PMID:
14513419
[PubMed - indexed for MEDLINE]
Free Article
13.

The influence of 3TC resistance mutation M184I on the fidelity and error specificity of human immunodeficiency virus type 1 reverse transcriptase.

Rezende LF, Drosopoulos WC, Prasad VR.

Nucleic Acids Res. 1998 Jun 15;26(12):3066-72.

PMID:
9611256
[PubMed - indexed for MEDLINE]
Free PMC Article
14.

Evolution of lamivudine resistance in human immunodeficiency virus type 1-infected individuals: the relative roles of drift and selection.

Frost SD, Nijhuis M, Schuurman R, Boucher CA, Brown AJ.

J Virol. 2000 Jul;74(14):6262-8.

PMID:
10864635
[PubMed - indexed for MEDLINE]
Free PMC Article
15.

The anti-HIV activity of entecavir: a multicentre evaluation of lamivudine-experienced and lamivudine-naive patients.

Sasadeusz J, Audsley J, Mijch A, Baden R, Caro J, Hunter H, Matthews G, McMahon MA, Olender SA, Siliciano RF, Lewin SR, Thio CL.

AIDS. 2008 May 11;22(8):947-55. doi: 10.1097/QAD.0b013e3282ffde91.

PMID:
18453854
[PubMed - indexed for MEDLINE]
Free PMC Article
16.

Mutation patterns of the reverse transcriptase genes in HIV-1 infected patients receiving combinations of nucleoside and non nucleoside inhibitors.

Re MC, Bon I, Monari P, Borderi M, Gibellini D, Schiavone P, Vitone F, Chiodo F, La Placa M.

Int J Antimicrob Agents. 2003 Oct;22(4):388-94.

PMID:
14522102
[PubMed - indexed for MEDLINE]
17.

Anti-human immunodeficiency virus type 1 activity and resistance profile of 2',3'-didehydro-3'-deoxy-4'-ethynylthymidine in vitro.

Nitanda T, Wang X, Kumamoto H, Haraguchi K, Tanaka H, Cheng YC, Baba M.

Antimicrob Agents Chemother. 2005 Aug;49(8):3355-60.

PMID:
16048947
[PubMed - indexed for MEDLINE]
Free PMC Article
18.

HIV-1 resistance profile of the novel nucleoside reverse transcriptase inhibitor beta-D-2',3'-dideoxy-2',3'-didehydro-5-fluorocytidine (Reverset).

Geleziunas R, Gallagher K, Zhang H, Bacheler L, Garber S, Wu JT, Shi G, Otto MJ, Schinazi RF, Erickson-Viitanen S.

Antivir Chem Chemother. 2003 Jan;14(1):49-59.

PMID:
12790516
[PubMed - indexed for MEDLINE]
19.

Mutations in HIV-1 reverse transcriptase during therapy with abacavir, lamivudine and zidovudine in HIV-1-infected adults with no prior antiretroviral therapy.

Ait-Khaled M, Rakik A, Griffin P, Cutrell A, Fischl MA, Clumeck N, Greenberg SB, Rubio R, Peters BS, Pulido F, Gould J, Pearce G, Spreen W, Tisdale M, Lafon S; CNA3003 International Study Team.

Antivir Ther. 2002 Mar;7(1):43-51.

PMID:
12008787
[PubMed - indexed for MEDLINE]
20.

Selection of drug-resistant HIV-1 during the early phase of viral decay is uncommon in treatment-naïve patients initiated on a three- or four-drug antiretroviral regimen including lamivudine.

Bergroth T, Ekici H, Gisslén M, Loes SK, Goh LE, Freedman A, Lampe F, Johnson MA, Sönnerborg A.

J Med Virol. 2009 Jan;81(1):1-8. doi: 10.1002/jmv.21363.

PMID:
19031460
[PubMed - indexed for MEDLINE]
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk